And that’s where it got us:
-
The start of the Kappa story. Headquarters established in Oslo with offices in the US and Germany. Dr. Inger Reidun Aukrust, together with her team, discovered a process to produce all-trans vitamin K2, MK-7 in a strictly controlled process, producing exceptionally pure MK-7.2006
-
Launch of the K2VITAL® product brand covering K2 MK-7 powders and oils2011
-
Launch of K2VITAL Delta –- the world’s first and only double-microencapsulated vitamin K2 securing stability in any formulation.2013
-
Kappa acquires Synthetica, a long-term partner specialiszed in drug and vitamin synthesis, analysis and R&D2016
-
Kappa acquires ppm.ingredients2016
-
Kappa crowned NutraChampion at Nutraingredients-Asia for its scientific and commercial MK-7 innovations2018
-
Kappa Bioscience signs research agreements with universities and hospitals around the globe
2019 -
Verdane Capital Partners becomes majority owner2019
-
Listed as one of NORWAY’s FASTEST GROWING TECHNOLOGY businesses in Deloitte’s annual roundup2020
-
Kappa Bioscience continues its geographical expansion by establishing US-based entity2020
-
Kappa joins Ecologi and workforce becomes climate positive
2021 -
Kappa Bioscience is acquired by Balchem
2022